Scarica l'app Stockscreener
6.69
0.90%
0.06
Dopo l'orario di chiusura:
6.71
0.02
+0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Precedente Chiudi:
$6.63
Aprire:
$6.65
Volume 24 ore:
1.21M
Relative Volume:
0.81
Capitalizzazione di mercato:
$930.75M
Reddito:
$62.04M
Utile/perdita netta:
$-533.34M
Rapporto P/E:
-1.7066
EPS:
-3.92
Flusso di cassa netto:
$-473.07M
1 W Prestazione:
+2.92%
1M Prestazione:
+17.16%
6M Prestazione:
+28.16%
1 anno Prestazione:
-9.96%
Intervallo 1D:
$6.585
$6.85
Intervallo di 1 settimana:
$6.4913
$7.06
Portata 52W:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Nome
Vir Biotechnology Inc
Settore
Industria
Telefono
415-906-4324
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Confronta VIR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
6.69 | 922.40M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Iniziato | Evercore ISI | Outperform |
| 2025-08-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-03-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Iniziato | SVB Leerink | Outperform |
| 2022-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2022-03-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-01-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-09-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-11 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Iniziato | Needham | Buy |
| 2020-03-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-02-27 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Iniziato | Robert W. Baird | Neutral |
| 2019-11-05 | Iniziato | Barclays | Overweight |
| 2019-11-05 | Iniziato | Cowen | Outperform |
| 2019-11-05 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com - Investing.com Canada
After Losing 25% in the Past Year, Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners Must Be Relieved by the Recent Gain - 富途牛牛
Vir Biotechnology (VIR) Gains Positive Outlook Amid Industry Acq - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpShould You Buy? - MarketBeat
Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy - simplywall.st
Can Vir Biotechnology (NASDAQ:VIR) Afford To Invest In Growth? - Yahoo Finance
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
Is Vir Biotechnology Inc a good long term investmentRSI Overbought/Oversold & Rapid Wealth Accumulation - earlytimes.in
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 191,854 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 22,000 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo! Finance Canada
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down After Insider Selling - MarketBeat
What drives Vir Biotechnology Inc stock priceStochastic Oscillator Alerts & You’ve Never Seen Stock Picks Like These - earlytimes.in
Vir Biotechnology director Sato sells $132k in stock By Investing.com - Investing.com Australia
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology director Sato sells $132k in stock - Investing.com
Vir Biotechnology Director Sells 22,000 Shares - TradingView
Chmn Sato Sells 22,000 ($132.1K) Of Vir Biotechnology Inc [VIR] - TradingView
Endurance (Cayman) Ltd Svf Sells 61,493 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 127,938 Shares of Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.1%What's Next? - MarketBeat
Vir Biotechnology (VIR) Stock Analysis Report | Financials & Insights - Benzinga
Vir Biotechnology Reports Q3 2025 Financial Results and Clinical Progress - MSN
Why analysts remain bullish on Vir Biotechnology Inc. stockJuly 2025 Gainers & Precise Swing Trade Entry Alerts - moha.gov.vn
Ensign Peak Advisors Inc Increases Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology’s Earnings Call: Achievements and Challenges - MSN
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 227,803 Shares - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 235,971 Shares - MarketBeat
Owner SVF Endurance (Cayman) Ltd Sells 463,774 ($2.9M) Of Vir Biotechnology Inc [VIR] - TradingView
SVF Endurance reports Vir (VIR) insider sales around $6 per share - Stock Titan
H.C. Wainwright Keeps Their Buy Rating on Vir Biotechnology (VIR) - The Globe and Mail
How to manage a losing position in Vir Biotechnology Inc.Weekly Stock Report & AI Enhanced Trade Execution Alerts - newser.com
Is Vir Biotechnology Inc. stock gaining market shareRisk Management & Long Hold Capital Preservation Tips - newser.com
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference - BioSpace
How Vir Biotechnology Inc. stock reacts to job market dataWeekly Trade Analysis & Consistent Income Trade Ideas - newser.com
What margin trends mean for Vir Biotechnology Inc. stockMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Vir Biotechnology (NASDAQ:VIR) CFO Sells $37,802.44 in Stock - MarketBeat
Will Vir Biotechnology Inc. stock deliver consistent dividendsTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Why Vir Biotechnology Inc. stock is favored by top institutionsJuly 2025 Momentum & Reliable Intraday Trade Alerts - newser.com
Vir Biotechnology EVP O’Byrne sells $37,782 in shares - Investing.com India
What to do if you’re stuck in Vir Biotechnology Inc.Market Trend Summary & Daily Stock Trend Reports - newser.com
How Vir Biotechnology Inc. stock reacts to oil pricesWeekly Volume Report & Target Return Focused Picks - newser.com
Vir Biotechnology EVP O’Byrne sells $37,782 in shares By Investing.com - Investing.com Nigeria
Vir Biotechnology Inc Azioni (VIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vir Biotechnology Inc Azioni (VIR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SATO VICKI L | Director |
Dec 01 '25 |
Sale |
6.00 |
22,000 |
132,070 |
1,188,391 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 26 '25 |
Sale |
6.39 |
127,938 |
817,652 |
13,982,271 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 28 '25 |
Sale |
6.44 |
61,493 |
396,015 |
13,920,778 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 25 '25 |
Sale |
6.38 |
235,971 |
1,505,495 |
14,110,209 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 24 '25 |
Sale |
6.15 |
227,803 |
1,400,783 |
14,346,180 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):